SCHEMBL5236340

SCHEMBL5236340

CCOC(=O)c1c(O)c2cc(Cl)c(Cl)cc2c(=O)n1CCC(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.40
BAZ2B Q9UIF8 1/20 0.39
BAZ2A Q9UIF9 1/20 0.39
LMNA P02545 2/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
KDM4E B2RXH2 3/20 0.36
MAPT P10636 2/20 0.36
RXFP1 Q9HBX9 2/20 0.36
GAA P10253 2/20 0.36
BCL2L1 Q07817 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
THRB P10828 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5236533 0.88 ALDH1A1 (0.41) ALDH1A1BAZ2BBAZ2ASMN1; SMN2KDM4E
SCHEMBL5238633 0.85 ALDH1A1 (0.48) ALDH1A1BAZ2BBAZ2AHTTSMN1; SMN2
SCHEMBL5237705 0.83 L3MBTL1 (0.37) ALDH1A1BAZ2BBAZ2ALMNAHTT
SCHEMBL5236351 0.81 BAZ2B (0.45) ALDH1A1BAZ2BBAZ2ASMN1; SMN2KDM4E
SCHEMBL5237473 0.81 ALDH1A1 (0.41) ALDH1A1BAZ2BBAZ2ALMNAHTT
SCHEMBL5238661 0.81 ATM (0.41) ALDH1A1BAZ2BBAZ2AKDM4EMAPT
SCHEMBL5241066 0.79 ALDH1A1 (0.42) ALDH1A1BAZ2BBAZ2ALMNASMN1; SMN2
SCHEMBL5238563 0.79 MAPT (0.52) ALDH1A1LMNAKDM4EMAPTGAA
SCHEMBL6108164 0.76 CRHBP (0.33) ALDH1A1GAANPSR1
SCHEMBL5236477 0.76 TNF (0.40) ALDH1A1KDM4EGAANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1355886-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2007-07-11 EP disclosed
US-7034039-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-25 US disclosed
US-20040082607-A1 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082607-A1 Fused heterocyclic compounds DPP7, DPP4, METAP1 ALDH1A1 387/4885BAZ2B 382/4885BAZ2A 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.